CCCC
CCCC
NASDAQ · Biotechnology

C4 Therapeutics Inc

$1.82
+0.11 (+6.43%)
As of Feb 8, 2:06 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 18.06M 17.10M 17.57M
Net Income 3.97M 3.03M 3.72M
EPS
Profit Margin 22.0% 17.7% 21.2%
Rev Growth +2.4% +6.2% +3.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 60.01M 64.70M 53.64M
Total Equity 63.83M 64.52M 70.28M
D/E Ratio 0.94 1.00 0.76
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 5.85M 5.37M 5.78M
Free Cash Flow 3.20M 3.54M 3.04M